Cardiometabolic Medicine
The need for consistent updates and agile content is imperative for today’s clinician to remain current on the continuum of scientific data. In no therapeutic area is this more essential than in “Cardiometabolic Medicine,” a new term meant to encompass the interconnected and debilitating diagnoses of diabetes mellitus, heart failure, coronary artery disease/acute coronary syndrome, progressive renal insufficiency, and related disorders such as hypertension, hyperlipidemia, and hyperkalemia. These areas are subject to frequent pivotal trial publications, guidelines updates, FDA action, and outcomes assessments.
Our Tweetorials
Your new source for free CE/CME via Twitter!
Each program provides 0.5hr – 1.0hr credit for physicians, pharmacists, and nurses.
The Nephrology Community’s Reception of New Phase 3 Data on Aldosterone Synthase Inhibitors for Difficult-to-Control Hypertension at ESC2025
2) You've already seen those data w/@PamTaubMD & u can still earn 🆓credit by checking out https://t.co/Jnm3I9eari. Now we take a look at...
Update on Non-Statin Lipid-Lowering Therapies from ESC 2025
2) Our expert faculty @DLBHATTMD @DrM_ODonoghue and Chris Cannon were your 👀and 👂for this subject in Madrid #ESC2025 and have also produced an...
The Potential for Targeted Inhibition of Factor XI/XIa to Provide Safe and Effective Protection from a Secondary Ischemic Noncardioembolic Stroke
2) Our returning expert faculty is Ashkan Shoamanesh MD @Ash_Shoamanesh, #Stroke #Neurologist @HamHealthSci & Associate Professor @McMasterU. He...
New Phase 3 Data from ESC on Management of Uncontrolled or Treatment-Resistant Hypertension with an Aldosterone Synthase Inhibitor
2) Our returning expert faculty is Pam R Taub MD @PamTaubMD, #Cardiologist & Prof Medicine @UCSDMedSchool 🇺🇸. She will be reporting &...
Is There a Safe and Effective Anticoagulation Strategy for Secondary Prevention of Non-Cardioembolic Ischemic Stroke?
2) Follow this 🧵for 0.5hr 🆓 CE/#CME ! Don’t miss the first, still available for credit, at https://t.co/9PIJq6mcL7. This edition comes from...
Non-Statin Cholesterol Management Update
2) Our returning expert faculty is Dr. Deepak L. Bhatt, MD, MPH, MBA, @DLBhattMD #Cardiologist and Director of @MountSinaiHeart at @MountSinaiNYC...
CURRENT STANDARD APPROACH TO SECONDARY PREVENTION OF ISCHEMIC, NON-CARDIOEMBOLIC STROKE OR HIGH-RISK TIA
2) Our returning expert faculty is Ashkan Shoamanesh MD @Ash_Shoamanesh, #Stroke #Neurologist @HamHealthSci & Associate Professor @McMasterU. He...
ATTR-CM: Genetics, Pathophysiology, Early Accurate Diagnosis, and Expanding Treatment Options
2) #Transthyretin #Amyloid (#ATTR) #Cardiomyopathy (#ATTR_CM) is now known to be underdiagnosed & much more common than we once thought. With...
The Importance to Cardiorenal Outcomes of Effective Blood Pressure Control and the Pathophysiologic Role of Aldosterone Dysregulation
2) This program is intended for #HCPs & is supported by an unrestricted educational grant from AstraZeneca. Statement of accreditation &...
UPDATE ON MANAGING THE INTERSECTION OF oHCM & HEART FAILURE: Summary of a Discussion at ESC-HF 2025
2) We report from a symposium led by Iacopo Olivotto @IacopoOlivotto from #Firenze 🇮🇹 along w/Christoph Maack @ChristophMaack from Comprehensive...
@Cardiomet_CE on Twitter
Your only source for ACCREDITED SoMe-delivered
serialized professional cardiometabolic education. Physicians, nurses, pharmacists–come one, come all!
On Twitter at @cardiomet_ce, we present a series of tweetorials, Twitter-delivered case studies, and Twitter Journal Clubs, each accredited for 0.5hr – 1.0hr CE/CME. Programs are presented by expert faculty in engaging and fully interactive format. Our unique program harnesses the reach, up-to-the-minute currency, and accessibility of social media to deliver a constant flow of accredited, interactive, expert-delivered educational programs to a multidisciplinary and interprofessional audience of engaged clinicians.